Monitoring and Adjusting Quadruple Heart Failure Therapy

Initial Monitoring Protocol

The European Society of Cardiology recommends monitoring blood pressure, renal function, and electrolytes 1-2 weeks after each dose increment, at 3 months, and subsequently at 6-month intervals when initiating or adjusting quadruple therapy with ACE inhibitors, beta-blockers, diuretics, and aldosterone antagonists 1, 2, 3
Measure blood pressure, serum creatinine, potassium, and sodium at baseline before initiation of quadruple therapy 1, 2
Assess for signs of congestion, such as raised jugular venous pressure, peripheral edema, and ascites, at baseline 4
Check heart rate, particularly if considering beta-blocker therapy, at baseline 4

The European Society of Cardiology recommends that an increase in creatinine up to 50% above baseline or up to 3 mg/dl is acceptable when initiating ACE inhibitor therapy 4
Potassium levels up to 5.5 mmol/l are acceptable when initiating ACE inhibitor therapy 4
If creatinine or potassium rises beyond acceptable limits, first discontinue non-essential medications, such as NSAIDs, non-essential vasodilators, potassium supplements, and potassium-retaining agents 4
For symptomatic hypotension, reconsider the need for nitrates, calcium channel blockers, and other vasodilators 5
Beta-blockers should not be stopped suddenly unless absolutely necessary due to the risk of rebound myocardial ischemia/infarction and arrhythmias; seek specialist advice before discontinuation 5

The European Society of Cardiology recommends increasing the dose of diuretic, combining loop diuretics and thiazides, and administering loop diuretics twice daily for insufficient response 1, 2, 8
If GFR <30 ml/min, do not use thiazides except as therapy prescribed synergistically with loop diuretics 1, 2
Avoid excessive diuresis before starting ACE inhibitor treatment; reduce or withhold diuretics for 24 hours if possible 1, 2, 3

Avoid NSAIDs during ACE inhibitor and aldosterone antagonist therapy as they worsen renal function and increase hyperkalemia risk 4, 1, 2, 3
Avoid potassium supplements during initiation of ACE inhibitor therapy and when using aldosterone antagonists 4, 1, 2
Discontinue calcium channel blockers unless absolutely essential (e.g., for angina or hypertension) 4

Advise patients to weigh themselves daily and increase diuretic dose if weight increases persistently by 1.5-2.0 kg 5
Instruct patients to report deterioration, such as tiredness, fatigue, and breathlessness, and that deterioration can usually be easily managed by adjustment of other medication 5
Patients should be advised not to stop beta-blocker therapy without consulting their physician 5